<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03150212</url>
  </required_header>
  <id_info>
    <org_study_id>2016-A01574-47</org_study_id>
    <nct_id>NCT03150212</nct_id>
  </id_info>
  <brief_title>Effect of Saccharomyces Cerevisiae on the Improvement of Gastro-intestinal Disorders Associated to IBS With C Phenotype</brief_title>
  <acronym>IBS-GO</acronym>
  <official_title>Randomized Double Blind Placebo-controlled Clinical Study : Effect of IBSIUM on the Improvement of Gastro-intestinal Disorders Associated to the Irritable Bowel Syndrome (IBS) With C Phenotype (Predominant-constipation)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lesaffre International</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lesaffre International</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective is to assess the effect of an 8-week daily supplementation with IbSium®
      (probiotic yeast Saccharomyces cerevisiae CNCM I-3856) on the improvement gastro-intestinal
      disorders associated to the type C IBS (constipation predominant).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 20, 2017</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Abdominal pain/discomfort score rated with Likert scale (ranging from 0 to 7)</measure>
    <time_frame>Week 5 to Week 8</time_frame>
    <description>Total AUC W5-W8 (expressed in a.u./day.week) of abdominal pain/discomfort calculated using the mean daily score rated with Likert scale (ranging from 0 to 7) from week 5 to week 8 (included)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">456</enrollment>
  <condition>Constipation-predominant Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Saccharomyces cerevisiae CNCM I-3856</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Saccharomyces cerevisiae CNCM I-3856</intervention_name>
    <description>2 capsules daily, just before the breakfast with a glass of water, during 8 weeks.</description>
    <arm_group_label>Saccharomyces cerevisiae CNCM I-3856</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 capsules daily, just before the breakfast with a glass of water, during 8 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Presenting IBS with predominant constipation according to the Rome IV criteria from at
             least 1 year and less than 10 years and without any possible doubt concerning
             confounding organic lesions (other organic pathologies having been excluded
             compliantly to the usual recommendations using differential diagnostic of chronic
             abdominal pain)

        Rome IV:

        A) Recurrent abdominal pain, with an average of at least 1 day a week within the last 3
        months, and associated with 2 following criteria:

          1. Related to defecation,

          2. Associated with a change in stool frequency,

          3. Associated with a change of the stools appearance.

        B) Onset of the above symptoms at least 6 months before the diagnostic,

        C) More than one-fourth (25%) of bowel movements with Bristol stool form types 1 or 2 and
        less than one-fourth (25%) of bowel movements with Bristol stool form types 6 or 7 (check
        during the last 14 days using the stools frequency questionnaire associated to the Bristol
        Stools Scale &quot;BSS&quot;),

          -  Score of abdominal pain/discomfort ≥ 2 and &lt; 6 (using a 0 to 7 Likert point scale;
             daily average during the last 14 days verified at V1),

          -  For non-menopausal women: with the same efficient contraception method since at least
             3 months before the start of the study, and accepting to maintain this program over
             the study (hormonal contraception, intrauterine device or surgical intervention). For
             menopausal women: with or without Hormone Replacement Therapy (HRT in place since less
             than 3 months before the start of the study are excluded) ,

        Exclusion Criteria:

          -  Suffering from gastro-intestinal troubles other than IBS: lactose intolerance, Crohn
             disease, ulcerative colitis, celiac disease (gluten intolerance), symptomatic
             diverticulosis,

          -  Suffering from an immunodeficiency or affected by a severe or progressive disease
             (cardiac, pukmonary, hepatic, renal, hematologic, infectious or neoplastic),

          -  Suffering from a metabolic trouble affecting the intestinal transit function or the
             nutrients absorption like diabetes or unbalanced thyroid dysfunction,

          -  Currently under symptomatic drug treatment acting on the intestinal sensitivity or
             motility (laxatives, antispasmodics, anxiolytics, antidepressants, analgesics and
             NSAIDs are authorized if consumed for more than 3 months with a stable dosage and
             maintained during the study; opioïds and narcotic analgesics are forbidden), or
             dietary supplementation which according to the investigator should affect study
             results or stopped within a too short time window before the V1 randomization visit
             (less than 4 weeks for oral antibiotics, pre- or probiotics, less than 2 weeks for
             oral antifungal and anti-diarrheal if gastroenteritis),

          -  Refusing to stop the consumption of probiotics, prebiotics, or symbiotics under
             dietary supplement presentation or &quot;health foods&quot; (i.e. Lactibiane®, BION®, ultra
             yeast, kefir or food stuffs like ACTIMEL®, ACTIVIA® or other probiotics enriched dairy
             product etc.),

          -  Pregnant or lactating woman or intenting to become pregnant within 3 months ahead,
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David GENDRE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Biofortis Mérieux NutriSciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippe DUCROTTE, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service d'Hépatogastroentérologie - CHU Rouen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pierre DESREUMAUX, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service de Gastroentérologie - Hôpital Huriez, CHU Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sophie SCHMID, CPM</last_name>
    <phone>+33(0)240205799</phone>
    <email>sophie.schmid@mxns.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>General pratices</name>
      <address>
        <city>France</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>General practicioners</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Eurofins Optimed</name>
      <address>
        <city>Gieres</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yves Donazzolo, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Créabio Rhône Alpes</name>
      <address>
        <city>Givors</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Fantino, Professor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Pasteur de Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Michel Lecerf, Professor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Biofortis Mérieux NutriSciences</name>
      <address>
        <city>Saint Herblain</city>
        <zip>44800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David GENDRE, PI</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 10, 2017</study_first_submitted>
  <study_first_submitted_qc>May 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2017</study_first_posted>
  <last_update_submitted>July 12, 2017</last_update_submitted>
  <last_update_submitted_qc>July 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Constipation</mesh_term>
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Digestive System Diseases</mesh_term>
    <mesh_term>Gastrointestinal Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

